ALB and neoplasm: Given that 98.6% of LD4172 is bound to plasma proteins (Supplementary Table 1), it is plausible that LD4172 may be “piggybacking” on albumin accumulation in tumors, thereby achieving tumor-selective RIPK1 degradation.